BPMC BLUEPRINT MEDICINES CORP US FDA Inspections 8-K Filing 2023 - FDA Clinical Hold Lifted Blueprint Medicines Corp announced that the FDA lifted its partial clinical hold on the Phase 1/2 VELA trial of BLU-222.Get access to all SEC 8-K filings of the BLUEPRINT MEDICINES CORP